Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) Signals for Healthy Controls Evoked Response Potential (ERP) Signals for Healthy Controls and Patients With Parkinson Disease

NCT02149498•Dr. Oren Cohen

Summary

A cornerstone in PD research is the investigation of neurophysiological changes as potential biomarkers that could help in tracking disease progression and response to therapies. Electroencephalography (EEG) could provide a non-invasive and relatively cheap tool for identification of such biomarkers. In this study we will use high-density electroencephalograph (EEG) recording, in order to develop a platform of biomarkers that could be more sensitive and reliable to disease progression and response to therapeutic intervention than standard clinical measures.

Eligibility

Age

40 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical features or secondary cause) and HC aged 40-80 years
•2. PD patients Hoehn and Yahr stages I to IVStable PD therapy

Exclusion Criteria

•In the investigator's opinion, any unstable or clinically significant condition that would impair the participants' ability to comply with study requirements.
•Patients or HC with significant psychiatric symptoms or history
•BDI score \<14
•MMSE \<25
•Treatment with neuroleptics.
•For PD patients: Hoehn and Yahr Stage 5
•PD Patients with severe dyskinesia or tremor
•PD Patients with atypical Parkinsonism or secondary Parkinsonism
•History or evidence of neurological problems: cerebrovascular disease, previous head injury or neurosurgical interventions.
•Currently with lice or open wounds on scalp.
+4 more criteria

Key Dates

Start Date

July 1, 2014

Primary Completion Date

July 1, 2016

Completion Date

July 1, 2016

Last Updated

May 29, 2014

Enrollment

100

ESTIMATED participants

Conditions

Parkinson Disease

Contacts

Naama Warman Alaluf, Msc

CONTACT

972-3-530-4931 naama.warmanalaluf@sheba.health.gov.il

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGNA

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 29, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) Signals for Healthy Controls Evoked Response Potential (ERP) Signals for Healthy Controls and Patients With Parkinson Disease

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

Montelukast in Parkinson Disease

Exercise for Cognitive Excellence in Parkinson's Disease

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations